MX2022004215A - Derivados de 2-azaespiro[3.4]octano como agonistas de m4. - Google Patents

Derivados de 2-azaespiro[3.4]octano como agonistas de m4.

Info

Publication number
MX2022004215A
MX2022004215A MX2022004215A MX2022004215A MX2022004215A MX 2022004215 A MX2022004215 A MX 2022004215A MX 2022004215 A MX2022004215 A MX 2022004215A MX 2022004215 A MX2022004215 A MX 2022004215A MX 2022004215 A MX2022004215 A MX 2022004215A
Authority
MX
Mexico
Prior art keywords
sup
agonists
azaspiro
oxa
octane derivatives
Prior art date
Application number
MX2022004215A
Other languages
English (en)
Inventor
Michael David Shultz
Keith Jendza
Edward Charles Hall
James Neef
Fan Yang
Xin Chen
Amy Calhoun
Kevin Matthew Gardinier
Nancy Labbe-Giguere
Daniel Steven Palacios
Ming Qian
Christopher G Thomson
Kate Yaping Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2022004215A publication Critical patent/MX2022004215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

En el presente documento se proporcionan compuestos de acuerdo con la Fórmula (I) (ver Fórmula) (I) o su sal farmacéuticamente aceptable, en donde R1, R2, R3, R5, y R7 se definen en el presente documento. También se proporcionan en el presente documento composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como el uso de dichos compuestos como agonistas del receptor M4.
MX2022004215A 2019-10-09 2020-10-07 Derivados de 2-azaespiro[3.4]octano como agonistas de m4. MX2022004215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912986P 2019-10-09 2019-10-09
PCT/IB2020/059431 WO2021070091A1 (en) 2019-10-09 2020-10-07 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists

Publications (1)

Publication Number Publication Date
MX2022004215A true MX2022004215A (es) 2022-05-03

Family

ID=72944206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004215A MX2022004215A (es) 2019-10-09 2020-10-07 Derivados de 2-azaespiro[3.4]octano como agonistas de m4.

Country Status (20)

Country Link
US (3) US11485742B2 (es)
EP (1) EP4041737A1 (es)
JP (1) JP7349567B2 (es)
KR (1) KR20220079608A (es)
CN (1) CN114555606A (es)
AR (1) AR120169A1 (es)
AU (1) AU2020364186B2 (es)
CA (1) CA3155589A1 (es)
CL (1) CL2022000892A1 (es)
CO (1) CO2022004391A2 (es)
CR (1) CR20220153A (es)
EC (1) ECSP22027784A (es)
IL (1) IL291600A (es)
JO (1) JOP20220084A1 (es)
MX (1) MX2022004215A (es)
PE (1) PE20221454A1 (es)
TW (1) TW202128703A (es)
UY (1) UY38907A (es)
WO (1) WO2021070091A1 (es)
ZA (1) ZA202202913B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3156320A1 (en) * 2019-10-09 2021-04-15 Novartis Ag 2-AZASPIRO[3,4] OCTANE DERIVATIVES USED AS M4 AGONISTS
WO2024059249A1 (en) * 2022-09-16 2024-03-21 Cerevel Therapeutics, Llc M4 activators/modulators and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276520A1 (en) 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
JP2008521821A (ja) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
CA2661503A1 (en) 2006-08-25 2008-02-28 Vitae Pharmaceuticals, Inc. Inhibitors of 11.beta. -hydroxysteroid dehydrogenase type 1
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
EP2344457A1 (en) 2008-10-29 2011-07-20 Grünenthal GmbH Substituted spiroamines
BRPI1007350B8 (pt) * 2009-01-26 2021-05-25 Israel Institute For Biological Res compostos espiro heterocíclicos bicíclicos
WO2012062752A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. RADIOLABELLED mGLuR2 PET LIGANDS
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
CA2842841C (en) 2011-07-27 2016-04-19 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as protein kinase inhibitors
WO2014039489A1 (en) 2012-09-07 2014-03-13 Zoetis Llc Spirocyclic derivatives as antiparasitic agents
DK2897948T3 (en) 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
EP3406609A1 (en) * 2014-02-06 2018-11-28 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic receptor agonists
NZ731118A (en) 2014-10-31 2023-05-26 Indivior Uk Ltd Dopamine d3 receptor antagonists compounds
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB2540998A (en) 2015-08-04 2017-02-08 Phagenesis Ltd Catheter
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
CA3024180A1 (en) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
TWI801540B (zh) 2018-03-23 2023-05-11 美商輝瑞大藥廠 哌嗪氮雜螺衍生物
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2020364186A1 (en) 2022-04-21
US20220411435A1 (en) 2022-12-29
US20240140959A1 (en) 2024-05-02
US11820778B2 (en) 2023-11-21
ZA202202913B (en) 2023-06-28
CL2022000892A1 (es) 2023-01-20
CO2022004391A2 (es) 2022-04-29
KR20220079608A (ko) 2022-06-13
AU2020364186B2 (en) 2023-11-30
US11485742B2 (en) 2022-11-01
CA3155589A1 (en) 2021-04-15
JOP20220084A1 (ar) 2023-01-30
CN114555606A (zh) 2022-05-27
IL291600A (en) 2022-05-01
ECSP22027784A (es) 2022-05-31
WO2021070091A1 (en) 2021-04-15
CR20220153A (es) 2022-05-03
UY38907A (es) 2021-05-31
US20210130365A1 (en) 2021-05-06
PE20221454A1 (es) 2022-09-21
JP7349567B2 (ja) 2023-09-22
TW202128703A (zh) 2021-08-01
JP2022551853A (ja) 2022-12-14
EP4041737A1 (en) 2022-08-17
AR120169A1 (es) 2022-02-02

Similar Documents

Publication Publication Date Title
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
WO2017176620A3 (en) SOLUBLE C5aR ANTAGONISTS
MX2022009524A (es) Agonistas heterociclicos de glp-1.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
AU2021239135B2 (en) Substituted pyrimidine or pyridine amine derivative, composition thereof, and medical use thereof
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
MX2021014680A (es) Derivado de benzotriazol.
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
WO2021026479A9 (en) Small molecule inhibitors of s1p2 receptor and uses thereof
MX2023006176A (es) Nuevos derivados de indazol acetileno.
MX2023002068A (es) Nuevos compuestos que tienen actividad inhibidora sobre el receptor de prostaglandina e2 y usos de los mismos.
MX2021015727A (es) Derivados de piridin-3-ilo.
MX2021014458A (es) Compuestos triciclicos.